SOURCE: Bollinger Report

December 07, 2011 09:00 ET

A Change in Tides - Featured Research on Regeneron Pharmaceuticals, Inc. and Amgen, Inc.

NEW YORK, NY--(Marketwire - Dec 7, 2011) - Today, www.BollingerReport.com introduced featured coverage of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Amgen, Inc. (NASDAQ: AMGN). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=REGN&sm2=AMGN.

Upcoming macro-economic 'tides of influence' are buoyed by crisis both home and abroad. Spanish and Italian yields continue to climb as efforts by the European Central Bank have stopped short of establishing sovereign bond guarantees for any one country. The result is historic yields and a grave concern for the solvency of interbank lending. Markets were drawn to concerns over domestic policy stalemates producing downgrade risks. Despite the situation, there continues to be unique value and opportunity found within careful discretion.

Bollinger Report screened and selected Regeneron Pharmaceuticals, Inc. for its current position within the healthcare industry. Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. A copy of this report featuring Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is available at: www.BollingerReport.com/index.php?sm1=REGN.

Bollinger Report is featuring Amgen, Inc. for its changing role within the healthcare industry. Amgen Inc. (Amgen) is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. To download researches and analysis on Amgen, Inc. (NASDAQ: AMGN) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=AMGN.

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact Information